“Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient Treated With a Novel Combination Treatment With Anti PDL1 Antibody (Durvalumab) and VEGFR2 Antibody (Ramucirumab)”. 2020. Archives of Clinical and Medical Case Reports 4 (1): 8-14. https://fortunejournals.org/ojs/index.php/acmcr/article/view/22266.